Stem Cell Transplantation for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to test whether regulatory T-cell reduction is possible and safe in myeloma subjects undergoing autologous stem cell transplantation (ASCT).
Do I need to stop taking my current medications for the trial?
The trial requires that you do not use systemic immunosuppressive medications, including corticosteroids and certain other drugs. If you are taking these, you would need to stop them to participate.
Is stem cell transplantation for multiple myeloma safe?
Stem cell transplantation for multiple myeloma has been generally well tolerated, but some patients experience side effects like cytokine release syndrome (a condition where the immune system releases too many proteins into the blood too quickly) and hematologic toxicities (blood-related side effects). While these treatments show promise, they can also have severe adverse events, so ongoing research is needed to better understand and manage these risks.12345
How does the treatment of Regulatory T-cell reduction differ from other treatments for multiple myeloma?
Regulatory T-cell reduction in multiple myeloma is unique because it focuses on decreasing the number of regulatory T cells, which are known to suppress the immune response against cancer cells. This approach aims to enhance the body's natural ability to fight the cancer, unlike traditional treatments that primarily target the cancer cells directly.56789
What data supports the effectiveness of the treatment for reducing regulatory T-cells in multiple myeloma patients?
Research suggests that higher levels of regulatory T-cells (a type of immune cell that can suppress the body's immune response) are linked to poorer outcomes in multiple myeloma patients. Reducing these cells might improve the effectiveness of treatments like donor lymphocyte infusions (DLIs) by enhancing the body's ability to fight the cancer.56789
Who Is on the Research Team?
Michael Bishop, MD
Principal Investigator
University of Chicago
Are You a Good Fit for This Trial?
This trial is for adults aged 21-70 with symptomatic multiple myeloma who are candidates for stem cell transplantation. They must have a life expectancy over 12 weeks, be HIV negative, not have active hepatitis B or C, and no major organ issues. Pregnant women, those on immunosuppressants or with autoimmune diseases cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo autologous stem cell transplantation (ASCT) with or without regulatory T-cell depletion
Recovery and Monitoring
Monitoring of regulatory T cell depletion and recovery, and incidence of autologous graft-versus-host disease
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Regulatory T-cell reduction
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Chicago
Lead Sponsor